Subscribe to RSS
Download PDF
DOI: 10.1055/s-0038-1627733
Pharmakologische Behandlung von Borderline-Persönlichkeitsstörungen
Empfehlung der Gesellschaft zur Erforschung und Therapie von Persönlichkeitsstörungen e. V.Pharmacotherapy of BorderlinePersonality DisorderPublication History
eingegangen am:
02 May 2014
angenommen am:
20 June 2014
Publication Date:
24 January 2018 (online)
Zusammenfassung
In den vergangenen Jahrzehnten wurden mehr als 30 randomisiert kontrollierte Therapiestudien zur pharmakotherapeutischen Behandlung der Borderline-Persönlichkeitsstörung publiziert. Dies ist mehr als bei jeder anderen Persönlichkeitsstörung, aber wenig im Vergleich zu anderen Erkrankungen wie etwa Depressionen und Schizophrenien. Daher geben die hier dargestellten Empfehlungen zur Pharmakotherapie nur einen groben Orientierungsrahmen. Kein Medikament ist zur Therapie zugelassen, und Psychotherapie sollte grundsätzlich bevorzugt werden. Dennoch kann eine Therapie mit Stimmungsstabilisierern und ggf. Antipsychotika der 2. Generation einzelne psychopathologische Symptome, z. B. Impulsivität oder Schwierigkeiten in der Kontrolle von Wut und Ärger positiv beeinflussen. Medikamente sollten kurzfristig und mit klaren Zielen verordnet werden. Polypharmazie ist wenn immer möglich zu vermeiden.
Summary
More than 30 randomised controlled studies investigating the pharmacotherapy of Borderline Personality Disorder have been published in the last decades. This is more compared to other forms of personality disorders, however little as compared to other psychiatric conditions such as depression and schizophrenia. The following recommendations can therefore propose only a rough framework for the pharmacotherapy of Borderline Personality Disorder. No drug is approved for therapy of this condition, and psychotherapy should be preferred. Nevertheless, mood stabilizers and certain second generation antipsychotics may help in controlling e. g. impulsive behaviour and outbursts of rage and anger. Drugs should only be prescribed for short periods of time and with defining clear goals. Polypharmacy should be avoided whenever possible.
-
Literatur
- 1 American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001; 158 (10 Suppl): 1-52.
- 2 Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of Borderline Personality Disorder. J Clin Psychiatry 2004; 65 (01) 104-9.
- 3 de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 04 (04) 479-86.
- 4 DGPPN. S2-Praxisleitlinien in Psychiatrie und Psychotherapie. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. Gäbel W, Falkai P. (Hrsg.). Band 1 Behandlungsleitlinie Persönlichkeitsstörungen. Heidelberg: Steinkopff. 2009
- 5 Dulz B, Schneider A. Borderline-Störungen – Theorie und Therapie. Stuttgart: Schattauer; 1995
- 6 Dulz B, Welge A. Zur medikamentösen Anxiolyse bei Borderline-Patienten. Persönlichkeitsstörungen 2003; 07: 253-62.
- 7 Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a doubleblind placebo-controlled pilot study. J Clin Psychiatry 2002; 63 (05) 442-6.
- 8 Hoffmann SO. Angst – ein zentrales Phänomen in der Psychodynamik und Symptomatologie des Borderline-Patienten. In: Kernberg OF, Dulz B, Sachsse U. (Hrsg.) Handbuch der Borderline-Störungen. Stuttgart: Schattauer; 2000
- 9 Hollander E. et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2000; 62 (03) 199-203.
- 10 Lieb K. et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010; 196 (01) 4-12.
- 11 Linehan MM. et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69 (06) 999-1005.
- 12 Loew TH. et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006; 26 (01) 61-6.
- 13 Moen R. et al. Efficacy of extended-release divalproex combined with “condensed” dialectical behavior therapy for individuals with borderline personality disorder. Ann Clin Psychiatry 2012; 24 (04) 255-60.
- 14 Nickel MK. et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163 (05) 833-8.
- 15 Nickel M. et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57 (05) 495-9.
- 16 Nickel MK. et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65 (11) 1515-9.
- 17 Oldham JM. Guideline watch: practice guideline for the treatment of patients with borderline personality disorder. Arlington, VA: American Psychiatric Association 2005; Retrieved from http://psychiatryonline.org/data/Books/prac/Borderline.watch.pdf (04 March 2014).
- 18 Pascual JC. et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008; 69 (04) 603-8.
- 19 Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol 2009; 24 (05) 270-5.
- 20 Rinne T. et al. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159 (12) 2048-54.
- 21 Salzman C. et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15 (01) 23-9.
- 22 Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-7.
- 23 Schulz SC. et al. Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week, randomised double-blind placebo-controlled study. Br J Psychiatry 2008; 193: 1-8.
- 24 Silk KR. The process of managing medications in patients with borderline personality disorder. J Psychiatr Pract 2011; 17 (05) 311-9.
- 25 Simpson EB. et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65 (03) 379-85.
- 26 Soler J. et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162 (06) 1221-4.
- 27 Soloff PH. et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 09 (04) 238-46.
- 28 Stoffers J. et al. Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews. 2010 doi:10.1002/14651858.CD005653.pub2
- 29 Tritt K. et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19 (03) 287-91.
- 30 Zanarini MC, Frankenburg F. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry 2001; 62 (11) 849-54.
- 31 Zanarini MC. et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2011; 72 (10) 1353-62.